|
|
||||||||
Department of Radiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey
Correspondence: For correspondence or reprints contact: Dandamudi V. Rao, PhD, Professor of Radiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, MSB F-451, 185 South Orange Ave., Newark, NJ 07103.
ABSTRACT
The importance of cellular dosimetry in both diagnostic and therapeutic nuclear medicine is becoming increasingly recognized. Methods: Experimental range-energy relations for electrons and alpha particles, along with derived geometric reduction factors, are used to calculate cellular absorbed fractions for these radiations. The resulting absorbed fractions are employed to calculate cellular S-values for several radionuclides. Results: Cellular absorbed fractions for monoenergetic electron sources with energies ranging from 0.1 keV to 1 MeV, distributed uniformly in the source region, are calculated for several target
source combinations including cell
cell, cell
cell surface, nucleus
nucleus, nucleus
cytoplasm and nucleus
cell surface. Similar data are also provided for monoenergetic alpha particle sources with energies ranging from 3 to 10 MeV. S-values are also conveniently tabulated for 32P, 86Rb, 89Sr, 90Y, 91Y, 114mIn, 131I. Auger-election-emitters 51Cr, 67Ga, 99mTc, 111In, 123I, 125I, 201Tl, 203Pb and the alpha emitter 210Po. In addition, S-values are given for radionuclides in the 212Pb, decay series, including 212Pb, 212Bi and 212Po. Both absorbed fractions and S-values are supplied for a number of different size cells and cell nuclei. Conclusions: With the absorbed fractions and S-values in hand, along with experimentally determined information on the biokinetics and subcellular distribution of the radionuclides, the cellular self-absorbed dose can be conveniently calculated.
Key Words: cellular dosimetry absorbed fractions S-values electrons alpha particles
This article has been cited by other articles:
![]() |
V. Kersemans, B. Cornelissen, M. D. Minden, J. Brandwein, and R. M. Reilly Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences J. Nucl. Med., September 1, 2008; 49(9): 1546 - 1554. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Champion, P. Zanotti-Fregonara, and E. Hindie CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution S Values for 131I in Spheres of Various Sizes J. Nucl. Med., January 1, 2008; 49(1): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Bailey, D. L. Costantini, Z. Cai, D. A. Scollard, Z. Chen, R. M. Reilly, and K. A. Vallis Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor J. Nucl. Med., September 1, 2007; 48(9): 1562 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Costantini, C. Chan, Z. Cai, K. A. Vallis, and R. M. Reilly 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer J. Nucl. Med., August 1, 2007; 48(8): 1357 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wicki, D. Wild, D. Storch, C. Seemayer, M. Gotthardt, M. Behe, S. Kneifel, M. J. Mihatsch, J.-C. Reubi, H. R. Macke, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma Clin. Cancer Res., June 15, 2007; 13(12): 3696 - 3705. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Reilly, P. Chen, J. Wang, D. Scollard, R. Cameron, and K. A. Vallis Preclinical Pharmacokinetic, Biodistribution, Toxicology, and Dosimetry Studies of 111In-DTPA-Human Epidermal Growth Factor: An Auger Electron-Emitting Radiotherapeutic Agent for Epidermal Growth Factor Receptor-Positive Breast Cancer J. Nucl. Med., June 1, 2006; 47(6): 1023 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. O'Donnell Nuclear Localizing Sequences: An Innovative Way to Improve Targeted Radiotherapy J. Nucl. Med., May 1, 2006; 47(5): 738 - 739. [Full Text] [PDF] |
||||
![]() |
P. Chen, J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells J. Nucl. Med., May 1, 2006; 47(5): 827 - 836. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Kassis and S. J. Adelstein Radiobiologic Principles in Radionuclide Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 4S - 12S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V.S.V. Neti and R. W. Howell Isolating Effects of Microscopic Nonuniform Distributions of 131I on Labeled and Unlabeled Cells J. Nucl. Med., June 1, 2004; 45(6): 1050 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chen, R. Cameron, J. Wang, K. A. Vallis, and R. M. Reilly Antitumor Effects and Normal Tissue Toxicity of 111In-Labeled Epidermal Growth Factor Administered to Athymic Mice Bearing Epidermal Growth Factor Receptor-Positive Human Breast Cancer Xenografts J. Nucl. Med., September 1, 2003; 44(9): 1469 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Akabani, S. J. Kennel, and M. R. Zalutsky Microdosimetric Analysis of {alpha}-Particle-Emitting Targeted Radiotherapeutics Using Histological Images J. Nucl. Med., May 1, 2003; 44(5): 792 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Y. Xue, N. J. Butler, G. M. Makrigiorgos, S. J. Adelstein, and A. I. Kassis From the Cover: Bystander effect produced by radiolabeled tumor cells invivo PNAS, October 15, 2002; 99(21): 13765 - 13770. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |